Serum Soluble Interleukin-2 Receptor as a Possible Biomarker for the Early Detection and Follow-up of Nivolumab-Induced Pneumonitis

J Thorac Oncol. 2019 May;14(5):e90-e91. doi: 10.1016/j.jtho.2018.12.028.

Authors

Kazufumi Yoshida¹, Yuko Morishima², Toshihiro Shiozawa¹, Kensuke Nakazawa¹, Masashi Matsuyama¹, Takumi Kiwamoto¹, Yosuke Matsuno¹, Ikuo Sekine³, Nobuyuki Hizawa¹

Affiliations

¹ Department of Pulmonary Medicine, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
² Department of Pulmonary Medicine, Division of Clinical Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. Electronic address: mk01a231@md.tsukuba.ac.jp.
³ Department of Medical Oncology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.

PMID: 31027748
DOI: 10.1016/j.jtho.2018.12.028

No abstract available

Publication types

Letter

MeSH terms

Adult
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Agents, Immunological / pharmacology
Biomarkers / metabolism*
Carcinoma, Non-Small-Cell Lung / complications*
Early Diagnosis
Follow-Up Studies
Humans
Lung Neoplasms / complications*
Male
Nivolumab / adverse effects*
Nivolumab / pharmacology
Nivolumab / therapeutic use*
Pneumonia / chemically induced*
Receptors, Interleukin-2 / blood*

Substances

Antineoplastic Agents, Immunological
Biomarkers
Receptors, Interleukin-2
Nivolumab